Literature DB >> 7433922

Dicloxacillin and flucloxacillin twice daily with probenecid in staphylococcal infections. A clinical and pharmakokinetic evaluation.

S A Hedström, G Kahlmeter.   

Abstract

The therapeutic efficacy of decloxacillin or flucloxacillin, 1--2 g orally with probenecid twice daily was evaluated in staphylococcal infections. Excellent results were obtained with this as long-term maintenance therapy in 4 patients with relapsing chronic osteomyelitis and in 6 patients with postoperative infections. No side effects were observed in these patients. In 35 patients with furunculosis twice daily administration of dicloxacillin was used as a primary therapeutic regimen. All healed, but 4 recurrencies occurred during a 3-month observation period after therapy. In 5 patients allergic reactions were noted. The unbound fraction of flucloxallin in serum exceeded MIC values of methicillin-susceptible Staphylococcus aureus during 11 of 24 h. Pharmacokinetic data on flucloxallin with and without probenecid are given.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7433922     DOI: 10.3109/inf.1980.12.issue-3.10

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

1.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

2.  Pharmacokinetics and distribution of flucloxacillin in pacemaker patients.

Authors:  P Anderson; G Bluhm; M Ehrnebo; L Herngren; B Jacobson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  In healthy volunteers, taking flucloxacillin with food does not compromise effective plasma concentrations in most circumstances.

Authors:  Sharon J Gardiner; Philip G Drennan; Ronald Begg; Mei Zhang; Jared K Green; Heather L Isenman; Richard J Everts; Stephen T Chambers; Evan J Begg
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.